MINI REVIEW article
Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1628195
Vorasidenib for IDH-Mutant Grade 2 Gliomas: Clinical Advances and Future Directions
Provisionally accepted
- Shanghai Shidong Hospital of Yangpu District, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Vorasidenib, a brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2), represents a significant advancement in the management of IDH-mutant gliomas. This review explores the clinical implications of its recent FDA approval for grade 2 IDH-mutant astrocytomas and oligodendrogliomas. We delve into the pivotal INDIGO trial, which demonstrated substantial improvements in progression-free survival, and discuss vorasidenib's pharmacokinetics, safety profile, and dosing guidelines. Additionally, we analyze its role within evolving treatment paradigms, including watchful waiting, IDH-targeted therapy, and integration with radiotherapy and chemotherapy. Comparative insights into traditional and novel approaches highlight the potential of vorasidenib to delay invasive therapies while preserving quality of life. Challenges such as adverse effects, long-term safety, and its application to higher-grade gliomas are also addressed. This comprehensive review underscores the transformative impact of vorasidenib and emphasizes the necessity of multidisciplinary care and patient-centered decision-making in glioma management. Keywor ds：Vorasidenib; Astrocytoma; Oligodendroglioma; IDH mutation; Targeted therapy 1. Intr oduction to Vor asidenib Grade 2 gliomas, encompassing IDH-mutant astrocytomas and oligodendrogliomas, are characterized by distinct clinical, radiological, and molecular features. Clinically, they often present in younger adults (20-40 years) with seizures, focal neurological deficits, or incidental findings on imaging.
Keywords: Vorasidenib, Astrocytoma, Oligodendroglioma, IDH mutation, targeted therapy
Received: 13 May 2025; Accepted: 16 Jun 2025.
Copyright: © 2025 Pan, Bao and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shepeng Wei, Shanghai Shidong Hospital of Yangpu District, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.